Jinyu Bio-technology Co., Ltd. (SHA:600201)
11.90
-0.10 (-0.83%)
Nov 17, 2026, 3:00 PM CST
Jinyu Bio-technology Revenue
Jinyu Bio-technology had revenue of 493.33M CNY in the quarter ending September 30, 2026, with 16.67% growth. This brings the company's total for the last twelve months to 1.60B, up 20.85% year-over-year. In the year 2025, Jinyu Bio-technology had annual revenue of 1.40B with 11.23% growth. That makes Jinyu Bio-technology the 16,180th largest company in the world by revenue and 2,924th in China.
Revenue (ttm)
1.60B
Revenue Growth
+20.85%
P/S Ratio
8.07
Revenue / Employee
852.62K
Employees
1,881
Market Cap
12.83B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Jinyu Bio-technology breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.40B | 140.96M | 11.23% |
| Dec 31, 2024 | 1.26B | -342.77M | -21.45% |
| Dec 31, 2023 | 1.60B | 69.56M | 4.55% |
| Dec 31, 2022 | 1.53B | -247.65M | -13.94% |
| Dec 31, 2021 | 1.78B | 194.41M | 12.29% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Anhui Anke Biotechnology (Group) | 2.34B |
| Tibet Cheezheng Tibetan Medicine | 2.23B |
| Inner Mongolia Furui Medical Science | 1.64B |
| Nanjing Vazyme Biotech | 1.56B |
| BrightGene Bio-Medical Technology | 1.34B |
| Sinocelltech Group | 1.14B |
| Acrobiosystems | 1.03B |
| GemPharmatech | 941.80M |